On February 12, 2020 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications, reported that it will release its financial results for the fourth quarter and full year of 2019 on Wednesday, March 4, 2020 (Press release, Evogene, FEB 12, 2020, View Source [SID1234554245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.

A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through March 4, 2019, and an archive of the webcast will be available on the Company’s website.

On February 12, 2020 BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, reported the dates for several key events (Press release, BioLife Solutions, FEB 12, 2020, View Source [SID1234554244]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q4 & FY2019 Earnings Conference Call

The Company’s fourth quarter and full year 2019 financial results will be released after market close on Wednesday, March 11, 2020 and the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company’s financial results and a general business update.

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 9098230. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.

Investor Conferences

Cowen 40th Annual Healthcare Conference; March 2-4, 2020: Boston Marriott Copley Place
2020 Stephens West Coast 1×1 Conference; March 12, 2020: The Palace Hotel, San Francisco
Oppenheimer 30th Annual Healthcare Conference; March 17-18, 2020: InterContinental New York Barclay
B. Riley FBR’s 21st Annual Institutional Investor Conference; May 20-21, 2020: Beverly Hilton
Scientific Conferences

CAR TCR Summit Europe; February 24-27, 2020: Hotel Novotel London West
Innate Killer Summit 2020 | Hanson Wade; March 24-26, 2020: Westin San Diego
Advanced Therapies Congress & Expo; March 30 – April 1, 2020: Business Design Centre, London
Massachusetts Association of Blood Banks (MABB); April 7-8, 2020: Mansfield, MA
American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting; April 24-29, 2020: San Diego Convention Center
American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting; May 12-15, 2020; Hynes Convention Center, Boston
Allogeneic Cell Therapies Summit 2020 | Hanson Wade; May 19-21, 2020; Sheraton Boston Hotel
ISCT Annual Meeting; May 27-30, 2020: Palais des congres de Paris, France

On February 12, 2020 Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) reported that it will host a webcast and conference call to discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2019, and provide a general business overview, on Wednesday, February 26, 2020, at 4:30 p.m. ET (1:30 p.m. PT) (Press release, Portola Pharmaceuticals, FEB 12, 2020, View Source [SID1234554243]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details
The live conference call on Wednesday, February 26, 2020, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 6192918. The webcast can be accessed live on the Investor Relations section of the Company’s website at View Source It will be archived for 30 days following the call.

On February 12, 2020 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that management will participate in the 9th Annual Leerink Partners Global Healthcare Conference on February 26, 2020 at 10:00am ET in New York City and the Cowen and Company 40th Annual Health Care Conference on March 3, 2020 at 10:40am ET in Boston (Press release, BioMarin, FEB 12, 2020, View Source [SID1234554242]). To access the events that are accessible by live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 12, 2020 GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, reported unaudited results for the year ended 31 December 2019 (Press release, GC Pharma, FEB 12, 2020, View Source [SID1234554241]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full Year 2019(2)

Growth(2)

Total revenues

KRW 1,369.7 billion

+2.6%

Operating profit

KRW 40.3 billion

(19.7%)

K-IFRS profit after taxation

KRW -11.3 billion

–

(1) Consolidated
(2) Results and percentages compared to the full financial year 2018

Financial Highlights

Delivered total revenue growth of 2.6% KRW 1.37 trillion (2018: KRW 1.33 trillion), all consolidated entities revenues grew plus compared to equivalent 2018 period.
Operating profit decreased 19.7% to KRW 40.3 billion (2018: KRW 41.9 billion), primarily due to an impact of investment in R&D and SG&A.
One off costs – including corporate tax bill and VAT result in regular tax investigation, evaluation loss of stock investment, impairment losses of tangible asset and penalties from local antitrust regulator related to subsidiary, Green Cross MS, and impairment losses of intangible assets – impacted on after tax profits, expected to progressively ease over the course of 2020.